Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $60,772.60 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,661 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the transaction, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. This represents a 7.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Monday, November 3rd, Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.56, for a total transaction of $78,927.04.

Nurix Therapeutics Stock Down 6.1%

Shares of NRIX traded down $1.07 during mid-day trading on Friday, hitting $16.52. The company had a trading volume of 1,561,160 shares, compared to its average volume of 1,267,247. The stock has a market cap of $1.27 billion, a PE ratio of -5.43 and a beta of 1.93. The business’s 50-day simple moving average is $18.50 and its 200-day simple moving average is $13.36. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. The company had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NRIX. Morgan Stanley set a $36.00 price target on Nurix Therapeutics and gave the company an “overweight” rating in a research report on Thursday, January 8th. Wall Street Zen cut shares of Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, October 11th. Royal Bank Of Canada upped their target price on Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday. Oppenheimer reduced their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a research report on Friday, October 10th. Finally, Stifel Nicolaus boosted their target price on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Arizona State Retirement System lifted its holdings in Nurix Therapeutics by 8.2% in the fourth quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock valued at $417,000 after buying an additional 1,674 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Nurix Therapeutics by 66.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock worth $93,000 after purchasing an additional 1,970 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Nurix Therapeutics by 13.9% during the second quarter. Teacher Retirement System of Texas now owns 18,404 shares of the company’s stock worth $210,000 after acquiring an additional 2,248 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in shares of Nurix Therapeutics by 16.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 18,104 shares of the company’s stock valued at $206,000 after purchasing an additional 2,522 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Nurix Therapeutics by 23.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,518 shares of the company’s stock worth $313,000 after buying an additional 3,118 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.